Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease

References

• Chaudhuri KR, Sauerbier A, Rojo JM, et al. The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord 2015;21(3):287-91
   PubMed Web of Science ®Google Scholar
• Zis P, Rizos A, Martinez-Martin P, et al. Non-motor symptoms profile and burden in drug naive versus long-term Parkinson’s disease patients. J Parkinsons Dis 2014;4(3):541-7
   PubMedGoogle Scholar
• Wu Y, Guo XY, Wei QQ, et al. Determinants of the quality of life in parkinson’s disease: results of a cohort study from Southwest China. J Neurol Sci 2014;340(1-2):144-9
   PubMed Web of Science ®Google Scholar
• Kim SR, So HY, Choi E, et al. Influencing effect of non-motor symptom clusters on quality of life in parkinson’s disease. J Neurol Sci 2014;347(1-2):310-15
   PubMed Web of Science ®Google Scholar
• Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-31
   PubMed Web of Science ®Google Scholar
• Ahlskog JE. Beating a dead horse: dopamine and parkinson disease. Neurology 2007;69(17):1701-11
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 2010;9(12):1200-13
   PubMed Web of Science ®Google Scholar
• Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 2008;255(2):255-64
   PubMed Web of Science ®Google Scholar
• Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289(1-2):18-22
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22(12):1689-707
   PubMed Web of Science ®Google Scholar
• Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63(11):2091-6
   PubMed Web of Science ®Google Scholar
• Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-8
   PubMed Web of Science ®Google Scholar
• Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27(6):1405-10
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001;56(6):730-6
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005;20(10):1255-63
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. Nature Reviews Neuroscience 2013;14(9):626-36
   PubMed Web of Science ®Google Scholar
• Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease A prospective cohort study. Neurology 2014;83(14):1253-60
   PubMed Web of Science ®Google Scholar
• Mak E, Su L, Williams GB, et al. Neuroimaging correlates of cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(8):862-70
   PubMed Web of Science ®Google Scholar
• Stav AL, Aarsland D, Johansen KK, et al. Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease. Parkinsonism Relat Disord 2015;21(7):758-64
   PubMed Web of Science ®Google Scholar
• Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(5):431-43
   PubMed Web of Science ®Google Scholar
• Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86(2):135-43
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-8
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54(2):407-11
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969-77
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351(24):2509-18
   PubMed Web of Science ®Google Scholar
• Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry 2009;80(1):18-23
   PubMed Web of Science ®Google Scholar
• Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28(5):215-19
   PubMed Web of Science ®Google Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 2007;22(8):1061-8
   PubMed Web of Science ®Google Scholar
• Borek LL, Chou KL, JH, Friedman Management of the behavioral aspects of Parkinson’s disease. Expert Rev Neurother 2007;7(6):711-25
   PubMedGoogle Scholar
• Zahodne LB, Fernandez HH. Parkinson’s psychosis. Curr Treat Options Neurol 2010;12(3):200-11
   PubMed Web of Science ®Google Scholar
• Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Mov Disord 2013;28(6):755-62
   PubMed Web of Science ®Google Scholar
• Association, A.P., Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 2003: ManMag
   Google Scholar
• Low-dose clozapine for the treatment of drug-induced psychosis in parkinson’s disease. The parkinson study group. N Engl J Med 1999;340(10):757-63
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689-95
   PubMed Web of Science ®Google Scholar
• Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40(5):832-4
   PubMed Web of Science ®Google Scholar
• Hack N, Fayad SM, Monari EH, et al. An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting. PLoS One 2014;9(3):e91545
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Roberts VJ, Evatt ML, et al. Quetiapine improves visual hallucinations in parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009;119(12):2196-205
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005;20(8):958-63
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007;22(3):313-18
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat 2009;5:327-32
   PubMed Web of Science ®Google Scholar
• Friedman JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord 2012;27(6):803-4
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383(9916):533-40
   PubMed Web of Science ®Google Scholar
• Friedman JH. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother 2013;14(14):1969-75
   PubMed Web of Science ®Google Scholar
• Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson’s disease: a review. Mov Disord 2007;22(3):297-308
   PubMed Web of Science ®Google Scholar
• Brown RG, Dittner A, Findley L, et al. The parkinson fatigue scale. Parkinsonism Relat Disord 2005;11(1):49-55
   PubMed Web of Science ®Google Scholar
• Cochrane GD, Rizvi S, Abrantes AM, et al. The association between fatigue and apathy in patients with either parkinson’s disease or multiple sclerosis. Parkinsonism Relat Disord 2015. [Epub ahead of print]
   Google Scholar
• Friedman JH, Friedman H. Fatigue in parkinson’s disease: a nine-year follow-up. Mov Disord 2001;16(6):1120-2
   PubMed Web of Science ®Google Scholar
• Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with parkinson’s disease. Neurology 2003;60(7):1119-24
   PubMed Web of Science ®Google Scholar
• Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with parkinson disease. Neurology 2008;71(7):481-5
   PubMed Web of Science ®Google Scholar
• Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with parkinson disease? Neurology 2004;63(10):1908-11
   PubMed Web of Science ®Google Scholar
• Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22(14):2070-6
   PubMed Web of Science ®Google Scholar
• Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One 2013;8(12):e81802
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, Methylphenidate, or their combination in geriatric depression: A randomized, Double-blind, Placebo-controlled Trial. Am J Psychiatry 2015;172(6):561-9
   PubMed Web of Science ®Google Scholar
• Marsh L, McDonald WM, Cummings J, et al. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21(2):148-58
   PubMed Web of Science ®Google Scholar
• Marsh L. Depression and parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep 2013;13(12):409
   PubMed Web of Science ®Google Scholar
• Gotham AM, Brown RG, Marsden CD. Depression in parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49(4):381-9
   PubMed Web of Science ®Google Scholar
• Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinson’s disease: A critical review updating recent literature. J Affect Disord 2015;184:216-24
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005;20(9):1161-9
   PubMed Web of Science ®Google Scholar
• Pae CU. Use of antidepressants for depression in patients with Parkinson’s disease. Expert Opin Pharmacother 2013;14(3):255
   PubMed Web of Science ®Google Scholar
• Bomasang-Layno E, Fadlon I, Murray AN, et al. Antidepressive treatments for Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2015;21(8):833-42
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(6):573-80
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson’s disease. Mov Disord 2009;24(9):1325-32
   PubMed Web of Science ®Google Scholar
• Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78(16):1229-36
   PubMed Web of Science ®Google Scholar
• Friedman JH, Weintraub D. Glad about SAD (PD). Neurology 2012;78(16):1198-9
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010;10:49
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Dobkin R.D, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry 2011;168(10):1066-74
   PubMed Web of Science ®Google Scholar
• Dobkin R.D, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24(4):206-14
   PubMed Web of Science ®Google Scholar
• Sproesser E, Viana MA, Quagliato EM, et al. The effect of psychotherapy in patients with PD: a controlled study. Parkinsonism Relat Disord 2010;16(4):298-300
   PubMed Web of Science ®Google Scholar
• Armento ME, Stanley MA, Marsh L, et al. Cognitive behavioral therapy for depression and anxiety in Parkinson’s disease: a clinical review. J Parkinsons Dis 2012;2(2):135-51
   Google Scholar
• Fernie BA, Kollmann J, Brown RG. Cognitive behavioural interventions for depression in chronic neurological conditions: A systematic review. J Psychosom Res 2015;78(5):411-19
   PubMed Web of Science ®Google Scholar
• Faber R, Trimble MR. Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 1991;6(4):293-303
   PubMed Web of Science ®Google Scholar
• Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1704-8
   PubMed Web of Science ®Google Scholar
• Ducharme S, Flaherty AW, Seiner SJ, et al. Temporary interruption of deep brain stimulation for Parkinson’s disease during outpatient electroconvulsive therapy for major depression: a novel treatment strategy. J Neuropsychiatry Clin Neurosci 2011;23(2):194-7
   PubMed Web of Science ®Google Scholar
• Vonloh M, Chen R, Kluger B. Safety of transcranial magnetic stimulation in Parkinson’s disease: a review of the literature. Parkinsonism Relat Disord 2013;19(6):573-85
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurology 2015;14(5):518-31
   PubMed Web of Science ®Google Scholar
• Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014;85(6):668-74
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002;14(4):461-2
   Google Scholar
• Djamshidian A, Friedman JH. Anxiety and depression in Parkinson’s disease. Curr Treat Options Neurol 2014;16(4):285
   PubMed Web of Science ®Google Scholar
• Henderson R, Kurlan R, Kersun JM, et al. Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992;4(3):257-64
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson’s disease: a cross-sectional observational study. Parkinsonism Relat Disord 2012;18(10):1084-8
   PubMed Web of Science ®Google Scholar
• Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2005;46(2):227-32
   PubMed Web of Science ®Google Scholar
• Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease--associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183-9
   PubMed Web of Science ®Google Scholar
• Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry 2014;14:19
   PubMed Web of Science ®Google Scholar
• Smith KM, Eyal E, Weintraub D, et al. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72(1):88-95
   PubMed Web of Science ®Google Scholar
• Marino L, Friedman JH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson’s disease. Int J Neurosci 2013;123(1):70-1
   PubMed Web of Science ®Google Scholar
• Schapira AH. Excessive daytime sleepiness in Parkinson’s disease. Neurology 2004;63(8 Suppl 3):S24-7
   PubMed Web of Science ®Google Scholar
• Ylikoski A, Martikainen K, Partinen M. Parasomnias and isolated sleep symptoms in Parkinson’s disease: a questionnaire study on 661 patients. J Neurol Sci 2014;346(1-2):204-8
   PubMed Web of Science ®Google Scholar
• Di Fabio N, Poryazova R, Oberholzer M, et al. Sleepwalking, REM sleep behaviour disorder and overlap parasomnia in patients with parkinson’s disease. Eur Neurol 2013;70(5-6):297-303
   PubMed Web of Science ®Google Scholar
• Verbaan D, van Rooden SM, van Hilten JJ, et al. Prevalence and clinical profile of restless legs syndrome in Parkinson’s disease. Mov Disord 2010;25(13):2142-7
   PubMed Web of Science ®Google Scholar
• Zeng J, Wei M, Li T, et al. Risk of obstructive sleep apnea in Parkinson’s disease: a meta-analysis. PLoS One 2013;8(12):e82091
   PubMed Web of Science ®Google Scholar
• Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson’s disease: many causes, few therapeutic options. J Neurol Sci 2012;314(1-2):12-19
   PubMed Web of Science ®Google Scholar
• Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson’s disease. Neurotherapeutics 2014;11(1):68-77
   PubMed Web of Science ®Google Scholar
• Friedman JH, Agarwal P, Alcalay R, et al. Clinical vignettes in parkinson’s disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci 2011;121(8):472-6
   PubMed Web of Science ®Google Scholar
• Lyons KE, Friedman JH, Hermanowicz N, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010;33(1):5-10
   PubMed Web of Science ®Google Scholar
• Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142(4):499-501
   PubMed Web of Science ®Google Scholar
• Lang AE, Johnson K. Akathisia in idiopathic parkinson’s disease. Neurology 1987;37(3):477-81
   PubMed Web of Science ®Google Scholar
• Cochrane GD, et al. Internal Tremor in Parkinson’s Disease, Multiple Sclerosis, and Essential Tremor. Parkinsonism Relat Disord 2015
   Google Scholar
• Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson’s disease: treatment with clozapine. Mov Disord 1993;8(2):171-4
   PubMed Web of Science ®Google Scholar
• Camp CD. Paralysis agitans and multiple sclerosis and their treatment 1913
   Google Scholar
• Booth G. Psychodynamics in parkinsonism. Psychosom Med 1948;10(1):1-14
   PubMed Web of Science ®Google Scholar
• Prick J. Genuine parkinsonism. A psychosomatic, anthropological-psychiatric approach. in Abs World Congress of Psychiatry Madrid 1966
   Google Scholar
• Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72(6):708-12
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27(10):1230-8
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in parkinson’s disease. Int J Geriatr Psychiatry 2004;19(1):1-8
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613-18
   PubMed Web of Science ®Google Scholar
• Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with parkinson’s disease. Mov Disord 2009;24(8):1217-21
   PubMed Web of Science ®Google Scholar